Informing chemical categories through the development of adverse outcome pathways

Issues in Toxicology

Volumn , Issue , 2013, Pages 44-71

  Przybylak, K R ^a   Schultz, T W ^b  

^a LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF TENNESSEE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84897504263     PISSN: 17577179     EISSN: 17577187     Source Type: Book Series    
DOI: 10.1039/9781849734400-00044     Document Type: Article

References (45)

1. T. W. Schultz, Adverse outcome pathways: A way of linking chemical structure to in vivo toxicological hazards in In Silico Toxicology: Principles and Applications, ed. M. T. D. Cronin and J. C. Madden, Royal Society of Chemistry, Cambridge., 2005, p. 346.
2. G. T. Ankley, R. S. Bennett, R. J. Erickson, D. J. Hoff, M. W. Hornung, R. D. Johnson, D. R. Mount, J. W. Nichols, C. L. Russom, P. K. Schmieder, J. A. Serrano, J. E. Tietge and D. L. Villeneuve, Adverse Outcome Pathways: A conceptual framework to support ecotoxicology research and risk assessment, Environ. Toxicol. Chem. 2010, 29, 730.
3. H. J. Clewell, P. R. Gentry, J. M. Gearhart, B. C. Allen and M. E. Andersen, Considering pharmacokinetic and mechanistic information in cancer risk assessments for environmental contaminants: examples with vinyl chloride and trichloroethylene, Chemosphere, 1995, 31, 2561.
4. D. L. Shuey, R. W. Setzer, C. Lau, R. M. Zucker, K. H. Elstein, M. G. Narotsky, R. J. Kavlock and J. M. Rogers, Biological modeling of 5-fluorouracil developmental toxicity, Toxicology, 1995, 102, 207.
5. C. Sonich-Mullin, R. Fielder, J. Wiltse, K. Baetcke, J. Dempsey, P. Fenner-Crisp, D. Grant, M. Hartley, A. Knaap, D. Kroese, I. Mangelsdorf, E. Meek, J. M. Rice and M. Younes, International Programme on Chemical Safety. IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis, Regul. Toxicol. Pharmacol., 2001, 34, 146.
6. National Research Council (NRC), Toxicity Testing in the 21st Century: A Vision and a Strategy, Washington, DC:The National Academies Pres., 2007.
7. The Organisation for Economic Co-operation and Development (OECD) (2011) Report of the Workshop on Using Mechanistic Information in Forming Chemical Categories. OEC. Environment, Health and Safety Publications Series on Testing and Assessment No. 138. ENV/JM/MONO(2011)8.
8. The Organisation for Economic Co-operation and Development (OECD) (2012) Proposal for a Template, and Guidance on Developing and Assessing the Completeness of Adverse Outcome Pathways. http://www.oecd.org/env/ehs/testing/ 49963554.pdf
9. T. W. Schultz, B. Diderich and S. Enoch, The OECD Adverse Outcome Pathway Approach a case study for skin sensitisation in Alterative Testing Strategies Progress Report 2011 & AXLR8-2 Workshop Report on a Roadmap to Innovative Toxicity Testing, ed. T. Seidle and H. Spielman., 2011, p. 288.
10. D. A. Keller, D. R. Juberg, C. Catlin, W. H. Farland, W. G. Hess, D. C. Wolf and N. G. Doerrer, Identification and characterization of adverse effects in 21st century toxicology, Toxicol. Sci. 2012, 126, 291.
11. S. J. Enoch, C. M. Ellison, T. W. Schultz and M. T. D. Cronin, A review of the electrophilic reaction chemistry involved in covalent protein binding relevant to toxicity. Crit. Rev. Toxicol., 2011. 41, 783.
12. I. Tsakovska, I. Pajeva, P. Alov and A. Worth, Recent advances in the molecular modeling of estrogen receptor-mediated toxicity, in Advances in Protein Chemistry and Structural Biology, ed. C. Christov, Academic Press, Burlington., 2011, p. 217.
13. J. Hooyberghs, E. Schoeters, N. Lambrechts, I. Nelissen, H. Witters, G. Schoeters, G. and R. Van Den Heuvel, A cell-based in vitro alternative to identify skin sensitizers by gene expression. Toxicol. Appl. Pharmacol., 2008, 231, 103.
14. A. B. Hill, The environmental and diseases: Association or causation?, Proc. Roy. Soc. Med., 1965, 58, 295.
15. D. C. Volz, S. Belanger, M. Embry, S. Padilla, H. Sanderson, K. Schirmer, S. Scholz and D. Villeneuve, Adverse outcome pathways during early fish development: a conceptual framework for identification of chemical screening and prioritization strategies, Toxicol. Sci., 2011, 123, 349.
16. K. H. Watanabe, M. E. Andersen, N. Basu, M. J. Caravan 3rd, K. M. Crofton, K. A. King, C. Sunol, E. Tiffany-Castiglioni and I. R. Schultz, Defining and modeling known adverse outcome pathways: domoic acid and neuronal signaling as a case study, Environ. Toxicol. Chem., 2011, 30, 9.
17. K. L. Yozzo, S. P. McGee and D. C. Volz, Adverse outcome pathways during zebrafish embryogenesis: A case study with paraoxon, Aquat. Toxicol., 2013, 126, 346.
18. The Organisation for Economic Co-operation and Development (OECD) (2012) The Adverse Outcome Pathway for Skin Sensitization Initiated by Covalent Binding to Proteins. Part 1. Scientific Evidence. Part 1 scientific evidence. OECD Environment, Health and Safety Publications Series on Testing and Assessment No. 168. ENV/JM/MONO(2012)10/PART1.
19. The Organisation for Economic Co-operation and Development (OECD) (2012) The Adverse Outcome Pathway for Skin Sensitization Initiated by Covalent Binding to Proteins. Part 2. Use of AOP to Develop Chemical Categories and Integrated Assessment and Testing Approaches. OECD Environment, Health and Safety Publications Series on Testing and Assessment No. 169. ENV/JM/MONO(2012)10/ PART2.
20. http://www.effectopedia.org/.
21. International Programme on Chemical Safety (IPCS), Mode of Action Framework, World Health Organization, Geneva., 2008.
22. The Organisation for Economic Co-operation and Development (OECD) (2011) Provision of Knowledge and Information: Hazard Assessment: Follow-up from the OECD Workshop on Using Mechanistic Information in Forming Chemical Categories: a Long-term Vision for the (Q)SAR Project. ENV/JM(2011)6.
23. The OECD QSAR Application Toolbox. (available from: http://www. qsartoolbox.org/).
24. Y. Sakuratani, H. Q. Zhang, S. Nishikawa, K. Yamazaki, T. Yamada, J. Yamada and M. Hayashi, Categorization of nitrobenzenes for repeated dose toxicity based on adverse outcome pathways, SAR QSAR Environ. Res., 2013, 24, 35.
25. R. H. Finnell, J. Gelineau-van Waes, J. D. Eudy and T. H. Rosenquist, Molecular basis of environmentally induced birth defects, Annu. Rev. Pharmacol. Toxicol., 2002, 42, 181.
26. I. Naruse, M. D. Collins and W. J. Jr. Scott, Strain differences in the teratogenicity induced by sodium valproate in cultured mouse embryos, Teratology, 1988, 38, 87.
27. J. Behrens and M. Kühl, Wnt signaling transduction pathways: An Overview, in Wnt Signaling in Development, ed. M. Kühl, Kluwer Academic/Plenum, Publishers, New York, 2003, p. 1.
28. N. Khan, M. Jeffers, S. Kumaar, C. Hackett, F. Boldog, N. Khramtsov, X. Qian, E. Mills, S. C. Berghs, N. Carey, P. W. Finn, L. S. Collins, A. Tumber, J. W. Ritchie, P. B. Jensen, H. S. Lichenstein and M. Sehested, Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors, Biochem. J., 2008, 409, 581.
29. J. M. Mehnert and W. K. Kelly, Histone deacetylase inhibitors: Biology and mechanism of action, Cancer., 2007, 13, 23.
30. C. J. Phiel, F. Zhang, E. Y. Huang, M. G. Guenther, M. A. Lazar and P. S. Klein, Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen, J. Biol. Chem., 2001, 276, 36734.
31. J. Wiltse, Mode of action: Inhibition of histone deacetylase, altering Wnt-dependnent gene expression and regulation of beta-catenin-Developmental effects of valproic acid, Crit. Rev Toxicol., 2005, 35, 727.
32. L. C. Fuller, S. K. Cornelius, C. W. Murphy and D. J. Wiens, Neural crest cell motility in valporic acid, Reprod. Toxicol., 2002, 16, 825.
33. D. A. Dawson, T. W. Schultz and R. S. Hunter, Developmental toxicity of carboxylic acids to Xenopus embryos: A quantitative structure-activity relationship and computer-automated structure evaluation, Teratogen. Carcinogen. Mutagen., 1996, 16, 109.
34. J. B. Wallingford and R. M. Harland, Neural tube closure requires disheveled-dependent convergent extension of the midline, Development., 2002, 129, 5815.
35. C. Yost, M. Tones, J. R. Miller, E. Huang, D. Kimelman and R. T. Moon, The axis-inducing activity, stability, and subcellular distribution of betacatenin is regulated in Xenopus embryos by glycogen synthase kinase 3, Genes Devel., 1996, 10, 1443.
36. C. Kliecker and C. Niehrs, A morphogen gradient of Wnt/b-catenin signaling regulates anterioposterior neural patterning in Xenopus, Development., 2001, 128, 4189.
37. J. B. Wang, N. S. Hamblet, S. Mark, M. E. Dickinson, B. C. Brinkman, N. Segil, S. E. Fraser, P. Chen, J. B. Wallingford and A. Wynshaw-Boris, Dishevelled genes mediate a conserved mammalian PCP pathway to regulate convergent extension during neurulation, Development, 2006, 133, 1767.
38. E. Robert and P. Guibaud, Maternal valproic acid and congenital neural tube defects, Lancet, 1982, 2, 937.
39. E. Robert and F. Rosa, Valproate and birth defects, Lancet, 1983, 2, 1.
40. E. J. DeCarlos, Structure-activity relationships (SAR) and structure metabolism relationships (SMR) affecting the teratogenicity of carboxylic acids, Drug Metab. Rev., 1990, 22, 411.
41. M. G. Narotsky, E. Z. Francis and R. J. Kavlock, Developmental toxicity and structure-activity relationship of aliphatic acids, including doseresponse assessment of valproic acid in mice and rats, Fundam. Appl. Toxicol., 1994, 22, 251.
42. B. Heltweg, J. Trapp and M. Jung, In vitro assays for the determination of histone deacetylase activity, Methods, 2005, 36, 332.
43. T. Ciossek, H. Julius, H. Wieland, T. Maier and T. Beckers, A homogenous cellular histone deacetylase assay suitable for compound profiling and robotic screening, Anal. Biochem., 2007, 371, 72.
44. http://www.sigmaaldrich.com/chemistry/chemistry-products.html? TablePage512916829
45. N. A. Brown, M. E. Coakley and D. O. Clarke, Structure-teratogenicity relationships of valproic acid congeners in whole-embyro culture, in Approaches to Elucidate Mechanism of Teratogenesis, ed. F. Welsch, Hemisphere, Washington, 1987, p. 17.